Endovascular MedTech

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (also known as "Endovascular MedTech™") was registered and established in 2012 at Shanghai International Medical Zone, and in 2019, it became one of the first companies to be listed on the STAR Market (688016.SH). Its business covers the research and development, production, sales, and service of interventional medical devices for the aorta, peripheral vasculature, and tumor interventions. The company currently has 30 products on the market globally, with 5 having obtained CE certification. Among the marketed and pipeline products, 9 have been approved to enter the national "green channel" for innovative medical device registration, positioning the company as a leader in the industry. As of March 2025, Endovascular MedTech™ products have been introduced into nearly 2,700 hospitals domestically and in over 40 countries and regions overseas, having saved or improved the quality of life for over 350,000 patients worldwide. In 2021, the company's domestic market share for aortic endovascular intervention products reached 29%.
Currently, the company's domestic business covers 31 provinces, autonomous regions, municipalities directly under the central government, as well as Hong Kong and Macau, while its international business spans Europe, Latin America, Asia, and other regions. Endovascular MedTech™ is always committed to the mission of providing "affordable, true, good, and beautiful solutions that extend and reshape lives" to the medical community, striving to become a leader in emerging technologies in the fields of major vessels and peripheral vasculature.